The protective effect of immunologic boosting against zoster: An analysis in leukemic children who were vaccinated against chickenpox

Journal of Infectious Diseases

Volumn 173, Issue 2, 1996, Pages 450-453

  Gershon, Anne A ^a   Larussa, Philip ^a   Steinberg, Sharon ^a   Mervish, Nancy ^a   Lo, Shaw Hwa ^a   Meier, Paul ^a  

^a The New York Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CHICKENPOX VACCINE;

ACTIVE IMMUNIZATION; ANTIBODY TITER; ARTICLE; CHICKENPOX; CHILD; CHILDHOOD CANCER; DOSE RESPONSE; DRUG EFFICACY; HUMAN; INFECTION PREVENTION; INFECTION SENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; REVACCINATION;

EID: 0030071133     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.2.450     Document Type: Article

References (15)

1. Mahalingham R, Wellish M, Wolf W, et al. Latent varicella-zoster viral DNA in human trigeminal and thoracic ganglia. N Engl J Med 1990;323:627-31.
2. Croen KD, Ostrove JM, Dragovic LY, Straus SE. Patterns of gene expression and sites of latency in human ganglia are different for varicellazoster and herpes simplex viruses. Proc Natl Acad Sci USA 1988;85:9773-7.
3. Lungu O, Annunziato P, Gershon A, et al. Reactivated and latent varicellazoster virus in human dorsal root ganglia. Proc Natl Acad Sci USA (in press).
4. Arvin AM, Pollard RB, Rasmussen L, Merigan T. Selective impairment in lymphocyte reactivity to varicella-zoster antigen among untreated lymphoma patients. J Infect Dis 1978;137:531-40.
5. Hardy IB, Gershon A, Steinberg S, et al. Incidence of zoster after live attenuated varicella vaccine [abstract]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 1991.
6. Morens DM, Bregman DJ, West M, et al. An outbreak of varicella-zoster virus infection among cancer patients. Ann Intern Med 1980;93:414-9.
7. Palmer SR, Caul EO, Donald DE, Kwantes W, Tillett H. An outbreak of shingles? Lancet 1985;2:1108-11.
8. Gershon AA, Steinberg S, Gelb L, NIAID Collaborative Varicella Vaccine Study Group. Live attenuated varicella vaccine: efficacy for children with leukemia in remission. JAMA 1984;252:355-62.
9. Gershon AA, Steinberg S, NIAID Collaborative Varicella Vaccine Study Group. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med 1989;320:892-7.
10. Gershon AA, Steinberg S, NIAID Collaborative Varicella Vaccine Study Group. Live attenuated varicella vaccine: protection in healthy adults in comparison to leukemic children. J Infect Dis 1990;161:661-6.
11. Hardy I, Gershon A. Prospects for use of a varicella vaccine in adults. Infect Dis Clin North Am 1990;4:160-73.
12. Williams V, Gershon A, Brunell P. Serologic response to varicella-zoster membrane antigens measured by indirect immunofluorescence. J Infect Dis 1974;130:669-72.
13. Martin JH, Dohner D, Wellinghoff WJ, Gelb LD. Restriction endonuclease analysis of varicella-zoster vaccine virus and wild type DNAs. J Med Virol 1982;9:69-76.
14. LaRussa P, Lungu O, Hardy I, Gershon A, Steinberg S, Silverstein S. Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J Virol 1992;66:1016-20.
15. Garnett GP, Grenfell BT. The epidemiology of varicella-zoster infections: a mathematical model. Epidemiol Infect 1992;108:495-511.